This is a working overview of Working solution, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-01 and is reviewed periodically as new material appears.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
== History == In the 1960s, Werner Bollag of Roche Laboratories began studying 13-cis retinoic acid as a treatment for skin cancer. By 1971, Roche showed that the compound was likely ineffective against cancer but useful for treating acne. However, Roche abandoned the product after finding a likelihood that the compound could cause birth defects, as the thalidomide scandal had raised the public's fear of such side effects. In 1975, Gary Peck, a dermatologist at the National Cancer Institute, initiated a collaboration with Hoffmann-La Roche to evaluate the efficacy of isotretinoin for a number dermatological conditions previously managed with retinoic acids, including acne, psoriasis, genetic skin disorders, and skin cancer prevention. After Peck authored an article in 1979 reporting the drug's effectiveness against cystic and conglobate acne, Roche submitted a New Drug Application to the Food and Drug Administration (FDA). While admitting that isotretinoin caused birth defects in rabbits, Roche avoided regulatory scrutiny by excluding pregnant women from its clinical trials and secured FDA approval in 1982. Despite prior correlation of isotretinoin with birth defects, Accutane quickly became the dominant acne treatment prescribed by dermatologists and general practitioners alike. In 1983, the FDA made the unprecedented decision to warn blood banks against accepting the blood of donors taking isotretinoin and instruct women to begin taking contraceptives one month before use.
Pseudomembranous candidiasis Erythematous candidiasis Denture stomatitis Antibiotic candidiasis Angular cheilitis Median rhomboid glossitis Chronic hyperplastic candidiasis Chronic mucocutaneous candidiasis
Myocardial infarction (MI) refers to tissue death (infarction) of a part of the heart muscle (myocardium), caused by ischemia, the lack of oxygen delivery to myocardial tissue. It is a type of acute coronary syndrome, which describes a sudden or short-term change in symptoms related to blood flow to the heart. Unlike the other type of acute coronary syndrome, unstable angina, a myocardial infarction occurs when there is cell death, which can be estimated by a blood test that measures biomarkers (the cardiac protein troponin). When there is evidence of an MI, it may be classified as an ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI) based on the results of an ECG. Another approach suggests categorizing MI as either occlusion myocardial infarction (OMI) or non-occlusion myocardial infarction (NOMI), depending on evidence of coronary occlusion on ECG. Preliminary research suggests that using OMI/NOMI above STEMI/NSTEMI leads to improved clinical outcomes, as such terminology does not limit the diagnosis of acute coronary occlusion to current STEMI criteria, which alone have poor sensitivity for MI. The phrase "heart attack" is often used non-specifically to refer to myocardial infarction. An MI is different from—but can cause—cardiac arrest, where the heart is not contracting at all or so poorly that all vital organs cease to function, thus leading to death. It is also distinct from heart failure, in which the pumping action of the heart is impaired. However, an MI may lead to heart failure.
Little Feat co-founder and pianist Bill Payne, known for his contributions to many of the band's early studio albums, was selected to temporarily fill in for Allison in his absence. The Doobies and Michael McDonald were the featured musical guests on The Tonight Show Starring Jimmy Fallon in 2015, where they performed a medley of "Long Train Runnin'" and "Takin' It to the Streets". The band also performed a web-exclusive performance of "What a Fool Believes" that was made available on The Tonight Show's website. In October 2015 Payne officially took over Guy Allison's duties as the Doobies' keyboardist, whilst remaining an active member of Little Feat. The next month, the Doobie Brothers together with Journey launched a tour featuring Dave Mason. The pairing with Journey continued in 2016, beginning at the Irvine Meadows Amphitheatre and concluding when the Doobies and Journey joined the Steve Miller Band and Santana at AT&T Park. They also appeared at Warren Haynes Christmas Jam in 2015, however Johnston did not appear due to knee surgery. In 2016 the Doobie Brothers signed under new management with Irving Azoff. Tony Pia left in the summer, leaving Ed Toth as the band's sole drummer. In 2017 the Doobie Brothers toured with Chicago once again, beginning at the Concord Pavilion and wrapping up in Virginia Beach. They also appeared with the Eagles and Steely Dan at the Classic concerts for two weekends in 2017. These concerts took place at Dodger Stadium (Classic West) and at Citi Field (Classic East).
Sources: en.wikipedia.org
The attack on the World Trade Center's North Tower alone made 9/11 the deadliest act of terrorism in history. Taken together, the four crashes killed 2,996 people (including the hijackers) and injured thousands more. The death toll included 265 on the four planes (from which there were no survivors); 2,606 in the World Trade Center and the surrounding area; and 125 at the Pentagon. Most who died were civilians, as well as 343 firefighters, 72 law enforcement officers, 55 military personnel, and the 19 terrorists. More than 90 countries lost citizens in the attacks. In New York City, more than 90% of those who died in the towers had been at or above the points of impact. In the North Tower, between 1,344 and 1,402 people were at, above or one floor below the point of impact and all died. Hundreds were killed instantly when the plane struck. The estimated 800 people who survived the impact were trapped and died in the fires or from smoke inhalation, fell or jumped from the tower to escape the smoke and flames, or were killed in the building's collapse. The destruction of all three staircases in the North Tower when Flight 11 hit made it impossible for anyone from the impact zone upward to escape. 107 people not trapped by the impact died. When Flight 11 struck between floors 93 and 99, the 92nd floor was rendered inescapable: the crash severed all elevator shafts while falling debris blocked the stairwells, ensuring the deaths of all 69 workers on the floor. In the South Tower, around 600 people were on or above the 77th floor when Flight 175 struck; few survived.
=== Manufacturing costs === The raw material consumption and the conversion cost are the two elements that establish the manufacturing cost for a particular fine chemical. The former is determined primarily by the unit consumption and the purchasing cost of the materials used; the latter, by the throughput in kilograms per day in a given production bay. A precise calculation of the conversion cost is a demanding task. Different products with widely differing throughputs are produced in campaigns in multipurpose plants, occupying the equipment to different extents. Therefore, both the production capacity and the equipment utilization for a specific fine chemical are difficult to determine. Moreover, cost elements such as labor, capital, utilities, maintenance, waste disposal, and quality control cannot be allocated unambiguously. An approximative calculation can be done by an experienced process development or pilot plant chemist on the basis of the laboratory synthesis procedure and by breaking down the process into unit operations, the standard costs of which have been determined previously. Controlling has to be involved for a more in-depth costing. It must fairly allocate costs for production capacity which is not used, whether because part of a production bay is idle, because of lack of demand or because a reactor is not required for a particular process. Manufacturing costs usually are reported on a per kilogram product basis. For the purpose of benchmarking (both internal and external), the volume x time/output (VTO) is a useful aid.
Instead, they reduce the release of excitatory neurotransmitters including glutamate, monoamine neurotransmitters and Substance P. Although not thought to be a major site of action, gabapentinoids such as gabapentin, but not pregabalin, have been found to activate Kv voltage-gated potassium channels (KCNQ). The endogenous α-amino acids L-leucine and L-isoleucine, which resemble the gabapentinoids in chemical structure (see figure) are ligands of the α2δ VDCC subunit with similar affinity as gabapentin and pregabalin (e.g., IC50 = 71 nM for L-isoleucine), and are present in human cerebrospinal fluid at micromolar concentrations (e.g., 12.9 μM for L-leucine, 4.8 μM for L-isoleucine). It has been hypothesized that they may be endogenous ligands of the subunit and that they may competitively antagonize the effects of gabapentinoids in brain tissues. In accordance, while gabapentin and pregabalin have nanomolar binding affinities for the α2δ subunit, their potencies in vivo are in the low micromolar range, and competition for binding by endogenous L-amino acids is likely responsible for this discrepancy. In one study, the affinity (Ki) values of gabapentinoids for the α2δ subunit expressed in rat brain were found to be 0.05 μM for gabapentin, 23 μM for (R)-phenibut, 39 μM for (S)-phenibut, and 156 μM for baclofen. Their affinities (Ki) for the GABAB receptor were >1 mM for gabapentin, 92 μM for (R)-phenibut, >1 mM for (S)-phenibut, 6 μM for Baclofen.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.